Switch to:
Also traded in: Canada, Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 1/10

vs
industry
vs
history
Cash to Debt 0.71
TEAR's Cash to Debt is ranked lower than
69% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.06 vs. TEAR: 0.71 )
Ranked among companies with meaningful Cash to Debt only.
TEAR' s Cash to Debt Range Over the Past 10 Years
Min: 0.09  Med: 10000.00 Max: No Debt
Current: 0.71
Equity to Asset 0.13
TEAR's Equity to Asset is ranked lower than
88% of the 183 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. TEAR: 0.13 )
Ranked among companies with meaningful Equity to Asset only.
TEAR' s Equity to Asset Range Over the Past 10 Years
Min: -1.1  Med: 0.70 Max: 0.96
Current: 0.13
-1.1
0.96
F-Score: 3
Z-Score: -27.20
M-Score: -5.63
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -128.48
TEAR's Operating margin (%) is ranked lower than
74% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.66 vs. TEAR: -128.48 )
Ranked among companies with meaningful Operating margin (%) only.
TEAR' s Operating margin (%) Range Over the Past 10 Years
Min: -48893.1  Med: -545.08 Max: -121.37
Current: -128.48
-48893.1
-121.37
Net-margin (%) -132.05
TEAR's Net-margin (%) is ranked lower than
75% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.98 vs. TEAR: -132.05 )
Ranked among companies with meaningful Net-margin (%) only.
TEAR' s Net-margin (%) Range Over the Past 10 Years
Min: -75902.17  Med: -496.14 Max: -120.31
Current: -132.05
-75902.17
-120.31
ROE (%) -181.74
TEAR's ROE (%) is ranked lower than
92% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.39 vs. TEAR: -181.74 )
Ranked among companies with meaningful ROE (%) only.
TEAR' s ROE (%) Range Over the Past 10 Years
Min: -214.14  Med: -97.25 Max: -53.26
Current: -181.74
-214.14
-53.26
ROA (%) -96.22
TEAR's ROA (%) is ranked lower than
91% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.60 vs. TEAR: -96.22 )
Ranked among companies with meaningful ROA (%) only.
TEAR' s ROA (%) Range Over the Past 10 Years
Min: -132.11  Med: -73.07 Max: -37.9
Current: -96.22
-132.11
-37.9
ROC (Joel Greenblatt) (%) -548.24
TEAR's ROC (Joel Greenblatt) (%) is ranked lower than
80% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.03 vs. TEAR: -548.24 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
TEAR' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -8269.06  Med: -4331.01 Max: -630.38
Current: -548.24
-8269.06
-630.38
Revenue Growth (3Y)(%) 69.10
TEAR's Revenue Growth (3Y)(%) is ranked higher than
97% of the 118 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.70 vs. TEAR: 69.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
TEAR' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 2.90 Max: 69.1
Current: 69.1
0
69.1
EBITDA Growth (3Y)(%) 18.60
TEAR's EBITDA Growth (3Y)(%) is ranked higher than
79% of the 99 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.90 vs. TEAR: 18.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
TEAR' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -77.8  Med: 12.60 Max: 97.5
Current: 18.6
-77.8
97.5
EPS Growth (3Y)(%) 12.50
TEAR's EPS Growth (3Y)(%) is ranked higher than
71% of the 110 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.10 vs. TEAR: 12.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
TEAR' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -78.5  Med: 12.50 Max: 71.6
Current: 12.5
-78.5
71.6
» TEAR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2014

TEAR Guru Trades in Q4 2014

Chuck Royce 100,000 sh (unchged)
» More
Q1 2015

TEAR Guru Trades in Q1 2015

Chuck Royce 113,000 sh (+13.00%)
» More
Q2 2015

TEAR Guru Trades in Q2 2015

Chuck Royce 100,000 sh (-11.50%)
» More
Q3 2015

TEAR Guru Trades in Q3 2015

Chuck Royce 100,000 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with TEAR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 7.40
TEAR's P/B is ranked lower than
85% of the 177 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.84 vs. TEAR: 7.40 )
Ranked among companies with meaningful P/B only.
TEAR' s P/B Range Over the Past 10 Years
Min: 0.18  Med: 3.04 Max: 63.48
Current: 7.4
0.18
63.48
P/S 1.06
TEAR's P/S is ranked higher than
80% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.78 vs. TEAR: 1.06 )
Ranked among companies with meaningful P/S only.
TEAR' s P/S Range Over the Past 10 Years
Min: 1.06  Med: 28.57 Max: 500
Current: 1.06
1.06
500
Current Ratio 2.39
TEAR's Current Ratio is ranked lower than
53% of the 191 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.68 vs. TEAR: 2.39 )
Ranked among companies with meaningful Current Ratio only.
TEAR' s Current Ratio Range Over the Past 10 Years
Min: 0.19  Med: 2.00 Max: 20.62
Current: 2.39
0.19
20.62
Quick Ratio 1.85
TEAR's Quick Ratio is ranked lower than
57% of the 191 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.41 vs. TEAR: 1.85 )
Ranked among companies with meaningful Quick Ratio only.
TEAR' s Quick Ratio Range Over the Past 10 Years
Min: 0.14  Med: 1.80 Max: 19.15
Current: 1.85
0.14
19.15
Days Inventory 106.52
TEAR's Days Inventory is ranked lower than
54% of the 153 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 88.26 vs. TEAR: 106.52 )
Ranked among companies with meaningful Days Inventory only.
TEAR' s Days Inventory Range Over the Past 10 Years
Min: 61.57  Med: 164.40 Max: 383.57
Current: 106.52
61.57
383.57
Days Sales Outstanding 36.27
TEAR's Days Sales Outstanding is ranked higher than
84% of the 155 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 65.71 vs. TEAR: 36.27 )
Ranked among companies with meaningful Days Sales Outstanding only.
TEAR' s Days Sales Outstanding Range Over the Past 10 Years
Min: 45.91  Med: 84.20 Max: 1487.77
Current: 36.27
45.91
1487.77
Days Payable 95.56
TEAR's Days Payable is ranked higher than
73% of the 149 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 52.88 vs. TEAR: 95.56 )
Ranked among companies with meaningful Days Payable only.
TEAR' s Days Payable Range Over the Past 10 Years
Min: 28.27  Med: 115.69 Max: 705.37
Current: 95.56
28.27
705.37

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 24.67
TEAR's Price/Tangible Book is ranked lower than
94% of the 156 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.14 vs. TEAR: 24.67 )
Ranked among companies with meaningful Price/Tangible Book only.
TEAR' s Price/Tangible Book Range Over the Past 10 Years
Min: 3.27  Med: 8.70 Max: 179.35
Current: 24.67
3.27
179.35
Price/Median PS Value 0.04
TEAR's Price/Median PS Value is ranked higher than
97% of the 157 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.91 vs. TEAR: 0.04 )
Ranked among companies with meaningful Price/Median PS Value only.
TEAR' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.1  Med: 0.97 Max: 13.72
Current: 0.04
0.1
13.72
Earnings Yield (Greenblatt) (%) -103.92
TEAR's Earnings Yield (Greenblatt) (%) is ranked lower than
92% of the 189 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.10 vs. TEAR: -103.92 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
TEAR' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -103.92  Med: 0.00 Max: 0
Current: -103.92
-103.92
0

More Statistics

Revenue(Mil) $24
EPS $ -0.94
Beta2.90
Short Percentage of Float9.76%
52-Week Range $0.74 - 3.15
Shares Outstanding(Mil)33.76

Analyst Estimate

Dec15 Dec16
Revenue(Mil) 36 44
EPS($) -1.37 -1.29
EPS without NRI($) -1.37 -1.29

Latest Earnings Webcast

» More Conference Calls

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:TLB.Canada, OCV1.Germany,
TearLab Corp was incorporated as OccuLogix, Inc. in Delaware in 2002. The Company is an in-vitro diagnostic company based in San Diego, California. The commercialized a proprietary tear testing platform, the TearLab Osmolarity System that enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. The Company's first product measures tear film osmolarity for the diagnosis of Dry Eye Disease, or DED. The Company's wholly-owned subsidiary, TearLab Research, Inc. develops technologies to enable eye care practitioners to test a range of biomarkers (chemistries, metabolites (glucose), genes and proteins) at the point-of-care. Commercializing that tear testing platform is the focus of the Company's business. The Company's first product, the TearLab Osmolarity System, enables the rapid measurement of tear osmolarity in the doctor's office. Osmolarity is a quantitative and specific biomarker that has been shown to assist in the diagnosis and disease management of DED. The innovation of the TearLab Osmolarity System is its ability to precisely and rapidly measure osmolarity in nanoliter volumes of tear samples, using an efficient and novel tear collection system at the point of care. The TearLab Osmolarity System consists of the following three components: the TearLab disposable, which is a single-use microfluidic microchip; the TearLab Pen, which is a hand-held device that interfaces with the TearLab disposable; and the TearLab Reader, which is a small desktop unit that allows for the docking of the TearLab Pen and provides a quantitative reading for the operator. The Company relies on two suppliers based in the United States for the manufacture of the Readers and Pens which are key components of the TearLab Osmolarity System. The Company also relies on a single supplier, MiniFAB (Aust) Pty Ltd. located in Australia, for the manufacture of the test cards which is also a key component of the TearLab Osmolarity System.
» More Articles for TEAR

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
TearLab Announces Fourth Quarter 2015 Preliminary Financial Estimates and Provides Corporate Update Feb 01 2016
TearLab Announces Proposed Public Offering of Common Stock Feb 01 2016
TEARLAB CORP Files SEC form 8-K, Results of Operations and Financial Condition, Costs Associated... Feb 01 2016
TearLab Announces Proposed Public Offering of Common Stock Feb 01 2016
TearLab Announces Fourth Quarter 2015 Preliminary Financial Estimates and Provides Corporate Update Feb 01 2016
TEARLAB CORP Files SEC form 8-K, Entry into a Material Definitive Agreement Jan 07 2016
TearLab Corp. Earnings Analysis: Q3, 2015 By the Numbers Dec 16 2015
TEARLAB CORP Files SEC form 8-K, Change in Directors or Principal Officers Dec 09 2015
TEARLAB CORP Financials Dec 08 2015
Here is What Hedge Funds Think About NanoViricides Inc (NNVC) Nov 27 2015
How Is Smart Money Trading CorMedix Inc. (CRMD)? Nov 23 2015
Edited Transcript of TEAR earnings conference call or presentation 5-Nov-15 9:30pm GMT Nov 10 2015
TearLab Corporation to Release Q3 2015 Financial Results on November 5, 2015 Nov 09 2015
TEARLAB CORP Files SEC form 10-Q, Quarterly Report Nov 06 2015
TearLab reports 3Q loss Nov 05 2015
TearLab reports 3Q loss Nov 05 2015
TEARLAB CORP Files SEC form 8-K, Results of Operations and Financial Condition, Change in Directors... Nov 05 2015
TearLab Corporation Reports Q3-15 Financial Results Nov 05 2015
TearLab to Participate in November Investor Conferences Nov 04 2015
TEARLAB CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits Oct 21 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK